Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL285694 | 0.83 | NPC1 (0.52) | NPC1RAB9APOLBMGLLMAOB | |
| SCHEMBL7008609 | 0.82 | KCNQ2 (0.62) | NPC1RAB9AHDAC3HDAC1HDAC2 | |
| SCHEMBL8251885 | 0.82 | RAB9A (0.55) | NPC1RAB9APOLBHDAC3HDAC1 | |
| SCHEMBL13193092 | 0.82 | RAB9A (0.55) | NPC1RAB9APOLBHDAC3HDAC1 | |
| Hydrochloric Acid SCHEMBL17653847 | 0.81 | NPC1 (0.53) | NPC1RAB9APOLBHDAC3HDAC1 | |
| SCHEMBL3811403 | 0.81 | NPC1 (0.68) | NPC1RAB9APOLBHDAC3HDAC1 | |
| SCHEMBL5716053 | 0.81 | RAB9A (0.63) | NPC1RAB9APOLBMGLLMAOB | |
| SCHEMBL5945338 | 0.81 | NPC1 (0.56) | NPC1RAB9APOLBMGLLMAOB | |
| SCHEMBL13261111 | 0.81 | NPC1 (0.56) | NPC1RAB9APOLBMGLLMAOB | |
| SCHEMBL19233183 | 0.80 | NPC1 (0.50) | NPC1RAB9APOLBMGLLMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3412670-B1 | PYRIDINE DERIVATIVES INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE THEREOF | SAMJIN PHARM CO LTD (KR) | 2022-03-09 | — | — | EP | disclosed |
| CN-109071543-B | Pyridine derivatives inhibiting RAF kinase and vascular endothelial growth factor receptor, process for their preparation, pharmaceutical compositions containing them and their use | 三进制药株式会社 | 2021-07-16 | — | — | CN | disclosed |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2020-11-24 | — | — | US | disclosed |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) | 2020-11-24 | — | — | US | disclosed |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-10-03 | — | — | US | disclosed |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | SAMJIN PHARMACEUTICAL CO., LTD. (KR) | 2019-10-03 | — | — | US | disclosed |
| EP-3412670-A1 | PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Samjin Pharmaceutical Co., Ltd. (KR) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017135589-A9 | PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 삼진제약주식회사 | 2017-10-19 | — | — | WO | disclosed |
| WO-2017135589-A1 | PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 삼진제약주식회사 | 2017-08-10 | — | — | WO | disclosed |
| EP-2647637-B1 | PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYL SULFONAMIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION WITH INHIBITORY ACTIVITY AGAINST RAF KINASE, CONTAINING SAME AS ACTIVE INGREDIENT | MEDPACTO INC (KR) | 2016-02-03 | — | — | EP | disclosed |
| US-9216981-B2 | Purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against Raf kinase, containing same as active ingredient | MEDPACTO, INC. (KR) | 2015-12-22 | — | — | US | disclosed |
| US-20130317023-A1 | NOVEL PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYL SULFONAMIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION WITH INHIBITORY ACTIVITY AGAINST RAF KINASE, CONTAINING SAME AS ACTIVE INGREDIENT | YOUAI CO., LTD. (KR) | 2013-11-28 | — | — | US | disclosed |
| EP-2647637-A2 | NOVEL PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYL SULFONAMIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION WITH INHIBITORY ACTIVITY AGAINST RAF KINASE, CONTAINING SAME AS ACTIVE INGREDIENT | Youai Co., Ltd. (KR) | 2013-10-09 | — | — | EP | disclosed |
| EP-0787720-B1 | PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KK (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-5994575-A | Phenylenediamines and process for preparing the same | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-30 | — | — | US | disclosed |
| US-5910498-A | NOVEL COMPOUNDS HAVING REDUCED CYTOTOXICITY, PHOTOTOXICITY; TREATING BACTERIAL AND VIRAL INFECTIONS | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1999-06-08 | — | — | US | disclosed |
| EP-0897909-A1 | NOVEL PHENYLENEDIAMINES AND PROCESS FOR PREPARING THE SAME | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-02-24 | — | — | EP | disclosed |
| EP-0787720-A1 | NOVEL PYRIDONECARBOXYLATE DERIVATIVE OR SALT THEREOF AND ANTIBACTERIAL CONTAINING THE SAME AS ACTIVE INGREDIENT | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317023-A1 | NOVEL PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYL SULFONAMIDE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION WITH INHIBITORY ACTIVITY AGAINST RAF KINASE, CONTAINING SAME AS ACTIVE INGREDIENT | BRAF, RAF1, ARAF | NPC1 4622/4885RAB9A 398/4885POLB 3157/4885 |
| US-20190300531-A1 | Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof | BRAF, KDR, RAF1 | NPC1 4847/4885RAB9A 933/4885POLB 3335/4885 |
| US-10844062-B2 | Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof | BRAF, KDR, RAF1 | NPC1 4847/4885RAB9A 933/4885POLB 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.